MRI for Lupus
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial explores whether a non-invasive MRI scan of the kidneys (Kidney MRI) can benefit people with systemic lupus erythematosus (SLE), an autoimmune disease affecting various body parts. The researchers aim to determine if these scans offer useful information for managing kidney involvement in lupus. Participants will undergo one to four MRI scans. The trial seeks adults diagnosed with SLE who have not had a kidney transplant and are not on dialysis.
As an unphased trial, this study allows participants to contribute to groundbreaking research that could enhance kidney care for lupus patients.
Will I have to stop taking my current medications?
The trial information does not specify whether you need to stop taking your current medications.
What prior data suggests that this MRI is safe for patients with lupus?
Research has shown that kidney MRI is generally safe. An MRI captures images of the body's interior without surgery or invasive tools, using magnets and radio waves. Studies have found that MRI, including kidney MRI, is usually well-tolerated, with few side effects or discomfort during the scan. Available studies report no serious problems linked to MRI. This method is widely used to diagnose and monitor various health conditions, indicating its high safety.12345
Why are researchers excited about this trial?
Researchers are excited about using kidney MRI for lupus because it offers a non-invasive way to monitor kidney health without needing a biopsy. Traditional methods for assessing lupus-related kidney issues often require invasive procedures like kidney biopsies, which can be uncomfortable and carry risks. MRI provides detailed images that could help doctors detect issues earlier and more accurately, potentially leading to better treatment outcomes. This approach could transform how doctors track kidney health in lupus patients, making it safer and less invasive.
What evidence suggests that a Kidney MRI is effective for systemic lupus erythematosus?
Research has shown that kidney MRI, which participants in this trial will undergo, can benefit people with lupus nephritis, a kidney problem caused by lupus. Studies have found that MRI can assess kidney damage without invasive procedures like biopsies. This imaging method helps doctors evaluate kidney appearance and function, aiding in treatment decisions. Early results suggest that MRI accurately reflects the kidney's health and damage level, making it a promising tool for monitoring kidney issues related to lupus. Overall, MRI provides a non-invasive way to track kidney health in lupus patients.13567
Who Is on the Research Team?
Homa Timlin, MD, MSc, MRCP, CCST
Principal Investigator
Johns Hopkins School of Medicine
Are You a Good Fit for This Trial?
This trial is for individuals with systemic lupus erythematosus (SLE) who may have kidney inflammation known as lupus nephritis. Details on specific inclusion and exclusion criteria are not provided, but typically participants would need to meet certain health standards.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
MRI Assessment
Participants undergo 1-4 kidney MRIs to evaluate inflammation, fibrosis, and atrophy
Follow-up
Participants are monitored for safety and effectiveness after MRI assessments
What Are the Treatments Tested in This Trial?
Interventions
- Kidney MRI
Kidney MRI is already approved in United States, European Union for the following indications:
- Diagnostic tool for lupus nephritis in systemic lupus erythematosus (SLE) patients
- Diagnostic tool for lupus nephritis in systemic lupus erythematosus (SLE) patients
Find a Clinic Near You
Who Is Running the Clinical Trial?
Johns Hopkins University
Lead Sponsor
Janssen Scientific Affairs, LLC
Industry Sponsor
Joaquin Duato
Janssen Scientific Affairs, LLC
Chief Executive Officer since 2022
MBA from ESADE, Master of International Management from Thunderbird School of Global Management
Dr. Jijo James, MD
Janssen Scientific Affairs, LLC
Chief Medical Officer since 2014
MD from St. Johns Medical College, MPH from Columbia University